Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00344305
Status:
COMPLETED
Last Update Posted:
2017-07-24
First Post:
2006-06-22
Brief Title:
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live Intranasal in Infants and Young Children
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
A Phase 2 Open-Label Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to Less Than 60 Months of Age
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Open label single arm multicenter study of the shedding and safety of a single dose of trivalent influenza virus vaccine live intranasal in children 6 to 60 months of age with 28-day shedding follow-up and 180-day safety follow-up
Detailed Description:
This was a Phase 2 open-label single-arm multicenter study designed to evaluate vaccine virus shedding and safety of trivalent influenza virus vaccine live intranasal in children 6 to 60 months of age Enrollment of approximately 200 participants was stratified by age with 100 participants 6 to 24 months of age who reached their sixth month but not their second year birthday and 100 participants 24 to 60 months of age who reached their second year but not their fifth year birthday Baseline medical history data collection included the participants prior receipt of influenza vaccine or history of laboratory-confirmed influenza illness in the previous influenza season
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None